Products - Children and young people | Topic

Showing 29 products

Date | Sort by Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over (HST20)
Product type:
Guidance
Programme:
Highly specialised technologies guidance
Published:
5 May 2022
Epilepsies in children, young people and adults (NG217)
Product type:
Guidance
Programme:
NICE guideline
Published:
27 April 2022
Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)
Product type:
Guidance
Programme:
Highly specialised technologies guidance
Published:
28 March 2022
Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education (NG213)
Product type:
Guidance
Programme:
NICE guideline
Published:
9 March 2022
Palforzia for treating peanut allergy in children and young people (TA769)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 February 2022
Risdiplam for treating spinal muscular atrophy (TA755)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 December 2021
Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal) (TA749)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 December 2021
Diabetes (type 1 and type 2) in children and young people: diagnosis and management – periodontal disease
Status:
In development
Programme:
NICE guideline
Expected publication date:
29 June 2022
Social, emotional and mental wellbeing in primary and secondary education
Status:
In development
Programme:
NICE guideline
Expected publication date:
6 July 2022
Self harm: assessment, management and preventing recurrence
Status:
In development
Programme:
NICE guideline
Expected publication date:
6 July 2022
Urinary tract infection in under 16s: diagnosis and management
Status:
In development | In consultation
Programme:
NICE guideline
Consultation end date:
25 May 2022
Expected publication date:
27 July 2022
Otitis media with effusion in under 12s
Status:
In development
Programme:
NICE guideline
Expected publication date:
28 September 2023
Maternal and child nutrition
Status:
In development
Programme:
NICE guideline
Expected publication date:
22 November 2023
Diabetes (type 1 and type 2) in children and young people: diagnosis and management - medicines for type 2 diabetes (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
3 January 2024
Fenfluramine for treating seizures associated with Dravet syndrome [ID1109]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Asfotase alfa for treating paediatric-onset hypophosphatasia (review of HST6) [ID3927]
Status:
Awaiting development
Programme:
Highly specialised technologies guidance
Expected publication date:
TBC
Beremagene geperpavec for treating dystrophic epidermolysis bullosa in children, young people and adults [ID3959]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vertebral body tethering for idiopathic scoliosis in children and young people
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TS ID 10085]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TS ID 10639]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Darunavir plus cobicistat fixed dose combination for paediatric human immunodeficiency virus 1 infection [TS ID 10722]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Somatrogon for treating growth disturbance in children and young people aged 3 and over [ID5086]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Eflornithine for maintenance treatment of high-risk neuroblastoma after 1 therapy in people up to 21 years [ID4060]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people 1 to 17 years [ID 5104]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dupilumab for children with severe atopic dermatitis [TS ID 10434]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Minimally invasive deformity correction system for the treatment of adolescent idiopathic scoliosis
Status:
Awaiting development
Programme:
Interventional procedures guidance
Expected publication date:
TBC

Children and young people Products

Filter

Product type
1 selected

Guidance programme

Status

New and updated
1 selected

Showing 29 products

Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over (HST20)

Epilepsies in children, young people and adults (NG217)

Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)

Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education (NG213)

Palforzia for treating peanut allergy in children and young people (TA769)

Risdiplam for treating spinal muscular atrophy (TA755)

Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal) (TA749)

Diabetes (type 1 and type 2) in children and young people: diagnosis and management – periodontal disease

Social, emotional and mental wellbeing in primary and secondary education

Self harm: assessment, management and preventing recurrence

Urinary tract infection in under 16s: diagnosis and management

Otitis media with effusion in under 12s

Maternal and child nutrition

Diabetes (type 1 and type 2) in children and young people: diagnosis and management - medicines for type 2 diabetes (update)

Fenfluramine for treating seizures associated with Dravet syndrome [ID1109]

Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]

Asfotase alfa for treating paediatric-onset hypophosphatasia (review of HST6) [ID3927]

Beremagene geperpavec for treating dystrophic epidermolysis bullosa in children, young people and adults [ID3959]

Vertebral body tethering for idiopathic scoliosis in children and young people

Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]

Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TS ID 10085]

Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]

Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TS ID 10639]

Darunavir plus cobicistat fixed dose combination for paediatric human immunodeficiency virus 1 infection [TS ID 10722]

Somatrogon for treating growth disturbance in children and young people aged 3 and over [ID5086]

Eflornithine for maintenance treatment of high-risk neuroblastoma after 1 therapy in people up to 21 years [ID4060]

Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people 1 to 17 years [ID 5104]

Dupilumab for children with severe atopic dermatitis [TS ID 10434]

Minimally invasive deformity correction system for the treatment of adolescent idiopathic scoliosis

Children and young people Products

Filter

Product type1 selected

Guidance programme

Status

New and updated1 selected

Showing 29 products

Product type
1 selected

New and updated
1 selected